Patents by Inventor Alan M. Easton

Alan M. Easton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7238507
    Abstract: The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceus spores. When the cDNA encoding the 11 alpha hydroxylase was co-expressed in Spodoptera frugiperda (Sf-9) insect cells with the cDNA encoding human oxidoreductase as an electron donor, it successfully catalyzed the conversion of the steroid substrate 4-androstene-3,17-dione (AD) to 11 alpha-hydroxy-AD as determined by HPLC analysis. The invention also relates to nucleic acid molecules associated with or derived from these cDNAs including complements, homologues and fragments thereof, and methods of using these nucleic acid molecules, to generate, for example, polypeptides and fragments thereof. The invention also relates to the generation of antibodies that recognizes the A.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: July 3, 2007
    Assignee: Pharmacia Corporation
    Inventors: Suzanne L. Bolten, Robert A. Clayton, Alan M. Easton, Leslie C. Engel, Dean M. Messing, John S. Ng, Beverly Reitz, Mark C. Walker, Ping T. Wang
  • Patent number: 7033807
    Abstract: The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceus spores. When the cDNA encoding the 11 alpha hydroxylase was co-expressed in Spodoptera frugiperda (Sf-9) insect cells with the cDNA encoding human oxidoreductase as an electron donor, it successfully catalyzed the conversion of the steroid substrate 4-androstene-3,17-dione (AD) to 11 alpha-hydroxy-AD as determined by HPLC analysis. The invention also relates to nucleic acid molecules associated with or derived from these cDNAs including complements, homologues and fragments thereof, and methods of using these nucleic acid molecules, to generate, for example, polypeptides and fragments thereof. The invention also relates to the generation of antibodies that recognizes the A.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: April 25, 2006
    Assignee: Pharmacia Corporation
    Inventors: Suzanne L. Bolten, Robert A. Clayton, Alan M. Easton, Leslie C. Engel, Dean M. Messing, John S. Ng, Beverly Reitz, Mark C. Walker, Ping T. Wang
  • Publication number: 20030148420
    Abstract: The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceus spores. When the cDNA encoding the 11 alpha hydroxylase was co-expressed in Spodoptera frugiperda (Sf-9) insect cells with the cDNA encoding human oxidoreductase as an electron donor, it successfully catalyzed the conversion of the steroid substrate 4-androstene-3,17-dione (AD) to 11 alpha-hydroxy-AD as determined by HPLC analysis. The invention also relates to nucleic acid molecules associated with or derived from these cDNAs including complements, homologues and fragments thereof, and methods of using these nucleic acid molecules, to generate, for example, polypeptides and fragments thereof. The invention also relates to the generation of antibodies that recognizes the A.
    Type: Application
    Filed: October 30, 2001
    Publication date: August 7, 2003
    Inventors: Bolten L. Suzanne, Robert A. Clayton, Alan M. Easton, Leslie C. Engel, Dean M. Messing, John S. Ng, Beverly Reitz, Mark C. Walker, Ping T. Wang
  • Patent number: 6153183
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: November 28, 2000
    Assignee: G. D. Searle & Company
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Patent number: 6030812
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 29, 2000
    Assignee: G. D. Searle & Company
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Patent number: 6022535
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 8, 2000
    Assignee: G. D. Searle & Company
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helen Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Patent number: 5604116
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids 119 to 133 have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: February 18, 1997
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark A. Abrams, Sarah R. Braford-Goldberg, Maire H. Caparon, Alan M. Easton, Barbara K. Klein, John P. McKearn, Peter Olins, Kumnan Paik, John W. Thomas
  • Patent number: 5543141
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins) in which segments of the polypeptide sequence of the human IL-3 polypeptide have been replaced by segments of the murine (mouse) interleukin-3 (mIL-3) polypeptide to form human/murine chimeric hybrid polypeptides. The human/mouse IL-3 may have amino acid deletions at the N-terminus or the C-terminus or at both the N- and C- termini and in some cases may also contain additional amino acid substitutions or deletions. The human/murine IL-3 muteins retain at least one biological activity of native hIL-3 and may also exhibit an improved side effects profile such as a reduction in the stimulation of leukotriene release or histamine release. The invention also relates to pharmaceutical compositions containing the h/m IL-3 hybrids and methods for using them.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 6, 1996
    Assignee: G.D. Searle & Co.
    Inventors: Sarah R. Braford-Goldberg, Alan M. Easton, Barbara K. Klein, John P. McKearn, Peter O. Olins
  • Patent number: 5501962
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins) in which segments of the polypeptide sequence of the human IL-3 polypeptide have been replaced by segments of the murine (mouse) interleukin-3 (mIL-3) polypeptide to form human/murine chimeric hybrid polypeptides. The human/mouse hybrid IL-3 may have amino acid deletions at the N-terminus or the C-terminus or at both the N- and C- termini and in some cases may also contain additional amino acid substitutions or deletions. The human/murine IL-3 muteins retain at least one biological activity of native hIL-3 and may also exhibit an improved side effects profile such as a reduction in the stimulation of leukotriene release or histamine release. The invention also relates to pharmaceutical compositions containing the h/m IL-3 hybrids and methods for using them.
    Type: Grant
    Filed: June 21, 1993
    Date of Patent: March 26, 1996
    Assignee: G. D. Searle & Co.
    Inventors: Sarah R. Braford-Goldberg, Alan M. Easton, Barbara K. Klein, John P. McKearn, Peter O. Olins